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ABSTRACT 
 
Serum hepcidin levels in ulcerative colitis - do they correlate with  
anemia and/or inflammation? 
 
Background to the study  
Anemia is a common complication of inflammatory bowel disease (IBD), which comprises 
Crohn’s disease (CD) and ulcerative colitis (UC). Hepcidin is known to be the central 
regulator of iron homeostasis in the body. It is up-regulated by inflammation and down-
regulated by anemia. Previous work has shown that serum hepcidin levels were decreased 
in patients with ulcerative colitis, who had co-existent anemia. This was surprising as these 
patients had a chronic inflammatory state. 
 
Aim: 
The aim of the present study was to test the hypothesis that when anemia and 
inflammation, which are opposing factors involved in regulation of hepcidin, co-exist in 
patients with UC, the effect of anemia on hepcidin predominates over that of inflammation.  
 
Materials and methods: 
A total of 59 patients were recruited into the study. Forty patients who were diagnosed to 
have ulcerative colitis by standard consensus criteria served as cases. Nineteen patients 
who attended the Gastroenterology clinic for investigation of dyspepsia and who were 
found to have no detectable abnormalities, who were non-anemic  (Hb > 12 g/dL for 
females and >13 g/dL for males) and who had no evidence of inflammation (serum CRP 
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levels < 6 mg/dL) served as control subjects. Informed consent was obtained for collecting 
blood from the study participants at the time of recruitment. Levels of serum ferritin, iron, 
hepcidin, C-reactive protein and hemoglobin were estimated in each sample. Data were 
analyzed using SPSS version 16, using appropriate tests. A p-value of <0.05 was 
considered to be statistical significant. 
 
Results: 
Levels of hemoglobin and serum iron and hepcidin were significantly lower and that of 
serum CRP were significantly higher in patients with ulcerative colitis, than in control 
patients. Levels of hemoglobin, serum ferritin, iron and hepcidin were significantly lower 
in patients with UC who were anemic than in those who were not. Levels of serum 
hepcidin correlated positively with hemoglobin, iron and ferritin.  
 
Conclusion:  
Serum hepcidin levels were significantly lower in patients with UC than in control 
subjects; they were also lower in UC patients who were anemic than in UC patients who 
were not.  Serum hepcidin levels correlated significantly with markers of iron status, but 
not with a marker of inflammation (CRP). Hence, it appears that when anemia and 
inflammation coexist, the influence of anemia on hepcidin predominated over that of 
inflammation. 
 
Keywords: Serum hepcidin, ulcerative colitis, anemia, iron 
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INTRODUCTION 
 
Iron, a transition metal, is an essential micronutrient. It is required for the synthesis of 
heme-containing proteins such as hemoglobin, myoglobin, catalase and 
cytochromes(Murray et al., 2012). In case of iron deficiency, hemoglobin synthesis is 
impaired and results in anemia. Iron deficiency can occur either due to increased loss of 
iron or decreased absorption of iron from the diet (Murray et al., 2012). On the other hand, 
iron in excess can cause detrimental effects to the cell by generating free radicals and 
inducing oxidative damage(Winterbourn, 1995). Thus, iron levels in the body have to be 
tightly controlled and regulated.   
 
Iron in circulation in the body is derived from two sources - dietary iron and iron recycled 
from senescent or worn-out erythrocytes. Hepcidin is a hormone that is known to be the 
central regulator of iron homeostasis in the body. It inhibits absorption of iron from the 
diet into the circulation and recycling of iron from macrophages in the reticulo-endothelial 
system (Murray et al., 2012). It is synthesized predominantly in hepatocytes and is 
excreted by the kidneys. It blocks iron efflux from cells by binding to, internalizing and 
degrading ferroportin, which is the iron-exporting protein found in mammalian cells  
(Nemeth et al., 2004b). Hepcidin is, in turn, regulated by iron availability, inflammation, 
infection and hypoxia (Nicolas et al., 2002). Inflammation is known to up-regulate 
hepcidin transcription and increase serum hepcidin levels (Nemeth et al., 2004a).  Hence, 
hepcidin levels are subjected to alterations in patients suffering from inflammatory 
disorders, like inflammatory bowel disease and rheumatoid arthritis. 
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INFLAMMATORY BOWEL DISEASE 
 
Inflammatory bowel disease (IBD) is a chronic disease of the digestive tract. It comprises 
Crohn's disease (CD) and ulcerative colitis (UC). Various etiologies have been proposed 
for these conditions; these include infections, allergies and immune mechanisms (Danese 
and Fiocchi, 2011). The most widely accepted view is that these are autoimmune diseases 
caused by dysregulated T-cell-mediated immune responses against endogenous commensal 
microbiota (Powrie et al., 1995). Normally, the mucosal immune system in the 
gastrointestinal tract does not react to endogenous commensals. Typical manifestations of 
the conditions include bloody diarrhea and abdominal pain, with periods of exacerbations 
and remissions. The peak age of onset follows a bimodal distribution, occurring between 
15- 30 years and 60-80 years (Freidman and Blummberg, 2011). UC affects males and 
females equally, whereas CD affects males and females in the ratio of 1.1-1.8 respectively 
(Freidman and Blummberg, 2011). The prevalence of UC is higher than that of CD.  
 
Ulcerative colitis  
The etiology, clinical features and diagnosis of ulcerative colitis are briefly reviewed 
below. The site of involvement in UC is most commonly the rectum. It extends proximally 
in a continuous fashion to involve the recto-sigmoid, the sigmoid and, in some cases, even 
the whole colon. A diagnosis of UC is based on the clinical picture, endoscopic appearance 
and histopathology results, which constitute consensus criteria (Freidman and Blummberg, 
2011). It is mostly a superficial disease limited to the mucosa and sub-mucosa, with 
ulceration being a predominant finding. The clinical features of UC include diarrhea, 
abdominal pain, intermittent rectal bleeding, tenesmus, passage of mucous in stools and 
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fever (Freidman and Blummberg, 2011). Intermittent rectal bleeding can result in either 
passage of frank blood or blood mixed with mucus.   
 
Anemia in ulcerative colitis 
Anemia is a chronic complication of inflammatory bowel disease. The prevalence of 
anemia in IBD is highly variable, ranging between 6 and 74% (Kulnigg and Gasche, 2006; 
Wilson et al., 2004). Anemia in these patients affects their quality of life (Pizzi et al., 2006; 
Wells et al., 2006). It is also the most common co-morbid condition associated with 
mortality in these patients (Cucino and Sonnenberg, 2001). Anemia is also the reason for 
frequent admissions and delayed discharge in those with UC (Liu and Kaffes, 2012). The 
causes of anemia include anemia of chronic disease, iron deficiency, vitamin B12 
deficiency, folate deficiency and/or immune- mediated hemolytic anemia. Of these, the 
most common causes are iron deficiency and anemia of chronic disease, with iron 
deficiency reported to be prevalent in 90% of cases (Kulnigg and Gasche, 2006). The 
pathophysiology of these two types of anemia is different. The cause of anemia in iron 
deficiency is due to intestinal blood loss from ulcerations in the gastrointestinal tract and 
impaired intestinal iron absorption (Gasche et al., 2004). The cause of anemia in ACD is 
due to reduced red cell survival, increased hepcidin levels and/or impaired response to 
erythropoietin (Freidman and Blummberg, 2011). The differentiation between these two 
types of anemia is critical for instituting the appropriate treatment in such patients.  
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IRON AND ITS IMPORTANCE 
 
Iron, a transition metal, is an essential micronutrient. It is required for the synthesis of 
heme-containing proteins, such as hemoglobin, myoglobin, catalase and cytochromes 
(Murray et al., 2012). When iron deficiency occurs, heme synthesis is impaired and results 
in anemia. Iron deficiency can occur either due to increased loss of iron from the body or 
decreased absorption of iron from the diet(Murray et al., 2012). On the other hand, excess 
of cellular iron can cause detrimental effects to the cell by participating in the Fenton 
reaction and generating free radicals (Winterbourn, 1995). Thus, iron levels in the body 
have to be tightly controlled and regulated. 
 
Iron in circulation in the body is derived from two sources - dietary iron and iron recycled 
from senescent red blood cells. The amount of iron absorbed from the diet is usually small 
compared to the amount of recycled iron from macrophages. Intestinal absorption of iron is 
the only route of entry of iron into the body. In humans, the excretion of iron is not 
regulated.  Therefore, intestinal iron absorption is of major importance in iron homeostasis 
(Wessling-Resnick, 2014).   
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Dietary iron 
Iron in the diet occurs mainly in two forms - heme and non-heme iron. Heme iron is 
derived from animal sources. Non-heme iron is derived from plant sources. The 
bioavailability of heme iron is higher than that of non-heme iron (Miret et al., 2003). Iron 
in the diet, either as heme or non-heme, enters the enterocyte and into the circulation. The 
degree of absorption of iron from the diet depends upon various factors such as iron levels 
in the circulation, the redox state of dietary iron and presence of compounds that can aid in 
or interfere with its absorption.  
 
Absorption of non-heme iron  
Non-heme iron in the diet exists in ferric form; this needs to be converted to its ferrous 
form,  as only the ferrous form of iron is absorbed (Wollenberg and Rummel, 1987). In the 
duodenum, a protein on the apical surface of duodenal enterocytes, duodenal cytochrome b 
reductase (dcyt b), converts ferric iron to its ferrous form (McKie et al., 2001). Once 
reduced by dcyt b, ferrous iron is transported into the enterocyte by a transporter protein 
called divalent metal transporter-1 (DMT-1)(Gunshin et al., 1997). Inside the enterocyte, 
iron enters the labile iron pool, from where it is transported into the circulation by 
ferroportin, a protein found on the basolateral aspect of the enterocyte, or it can be stored 
inside the enterocyte as ferritin (Evstatiev and Gasche, 2012). 
 
Dcyt b  
This is found on the apical surface of enterocytes of the proximal duodenum (McKie et al., 
2001). It is a ferri-reductase enzyme; it needs ascorbate as electron donor to reduce luminal 
ferric iron to its ferrous form (Su and Asard, 2006). Expression of this enzyme is up-
regulated in iron deficiency to enhance absorption of iron (McKie et al., 2001). Its role in 
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physiological iron absorption is, however, uncertain, as dcytb knock-out mice have been 
shown to maintain normal iron levels (Gunshin et al., 2005). However, under conditions of 
stress, such as hypoxia, dcytb knock-out mice showed significantly lower splenic iron 
levels and decreased hemoglobin synthesis, suggesting that dcyt b is essential during 
conditions of enhanced erythropoiesis (Choi et al., 2012). Hypoxia-inducible factor-2 alpha 
(HIF-2α), in particular, is known to up regulate dcytb (Luo et al., 2014). 
 
DMT-1 (divalent metal transporter 1) 
DMT1 is a transmembrane protein responsible for iron uptake into intestinal cells. It is 
made up of 12 transmembrane domains and belongs to the Nramp (natural resistance-
associated macrophage protein) family of proteins. It is also known as Nramp-2 or 
SLC11A2. It is found on the apical surface of enterocytes. It is also present in endosomes 
involved in the transferrin cycle, where it transfers iron out of the endosome, allowing it to 
be reutilized. A proton is co-transported, along with Fe2+, by DMT-1. It is highly expressed 
in the proximal duodenum and is mainly involved in iron absorption (Gunshin et al., 1997). 
Apart from iron (Fe2+), it also transports other divalent cations like Zn2+, Cu2+, Co2+, Pb2+, 
Cd2+, Mn2+ and Ni2+ (Gunshin et al., 1997). DMT-1 has a significant role in iron uptake, 
unlike dcytb, as suggested by development of autosomal microcytic hypochromic anemia 
in Belgrade (b) rat and microcytic anemia (mk) mice, which are animal models with a 
missense mutation in the DMT-1 gene (Fleming et al., 1998 and 1997). This mutation 
resulted in decreased intestinal iron absorption and erythroid iron uptake, explaining the 
phenotype in these animals. DMT-1 expression is modulated by iron availability, thus 
making it as a target for pharmacological intervention in iron overload disorders (Andrews, 
1999).  It has also been postulated to play a role in the uptake of non-transferrin-bound iron 
(NTBI) (Garrick et al., 1999). 
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Absorption of heme iron 
Heme iron is derived from proteolytic degradation of heme-containing proteins, by 
digestive enzymes in the intestine. Heme iron is absorbed into the enterocyte by heme 
transporters in the apical membrane of these cells (Shayeghi et al., 2005). Heme 
oxygenase-1 (HO-1), a cytosolic enzyme in the enterocyte, releases ferrous iron (Fe2+) 
from heme (Raffin et al., 1974). The fate of ferrous iron released is the same as that of non-
heme dietary iron.  
 
Iron efflux from enterocytes 
Iron inside the enterocyte is exported into the circulation by ferroportin. This is a multiple-
transmembrane domain protein and is the only known exporter of iron (Donovan et al., 
2000). It is also known as IREG1, MTP-1 or SLC 40A1(Donovan et al., 2005; McKie et 
al., 2000). It is expressed in proximal duodenal enterocytes, macrophages, placenta and, to 
a lower extent, in hepatocytes (Abboud and Haile, 2000; Donovan et al., 2000; McKie et 
al., 2000). It is located on the basolateral membrane of cells and plays a major role in iron 
absorption. Its expression is regulated by hepcidin, the central regulator of iron 
homeostasis and also by iron availability and  hypoxia (Donovan et al., 2005; Nemeth et 
al., 2004c).  
 
Fe2+, transported across the basolateral membrane by ferroportin, is oxidized to ferric form 
Fe3+ by hephaestin and released into the circulation. Hephaestin is a multicopper 
ferroxidase, homologous to ceruloplasmin (Vulpe et al., 1999). It plays a significant role in 
iron absorption. This is based on the development of sex-linked anemia (SLA) in mice 
with a mutation in the hephaestin gene. These SLA mice showed normal iron absorption 
but impaired release of iron into circulation (Vulpe et al., 1999).  
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Recycling of iron 
As mentioned earlier, the contribution of recycled iron to circulating iron is much greater 
than that of dietary iron.  Senescent erythrocytes are engulfed by macrophages, resulting in 
the formation of phagolysosomes. Inside the phagolysosome, heme oxygenase-1 (HO-1) 
acts on the heme and releases ferrous iron, which is transported into the cytoplasm by 
DMT-1 (Poss and Tonegawa, 1997; Tabuchi et al., 2000). Ferrous iron in the cytoplasm 
can either enter the labile iron pool, be stored as ferritin or transported out of the 
macrophage by ferroportin (Donovan et al., 2005). In the circulation, the ferrous form is 
converted to ferric form by ceruloplasmin, which acts as a ferroxidase (Harris et al., 1999). 
The ferric form of iron binds to transferrin (Tf). 
 
Fate of iron in the circulation 
Iron is transported in the circulation bound to a protein, apo-transferrrin (Baker N, 1994). 
In terms of structure, apo- transferrin is a bi-lobed glycoprotein and is able to reversibly 
bind two ferric ions. In normal conditions, 30-40% of the binding sites on transferrin are 
occupied by iron. This is measured in terms of transferrin saturation, which is used as an 
index of iron status (Freidman and Blummberg, 2011).  
 
In conditions of iron overload, the capacity of transferrin to bind iron is exceeded (Barisani 
et al., 1995). Unbound iron that accumulates in circulation is called non-transferrin-bound 
iron (NTBI). The mechanism by which NTBI is taken up into cells is not well understood. 
NTBI uptake by the various cells in the body can lead to various disorders; accumulation 
in cardiac myocytes, beta cells of the pancreas and neurons leads to cardiomyopathy 
(Oudit et al., 2003), diabetes mellitus type 2 (Kunutsor et al., 2013) and  ataxia and other 
demyelinating disorders, respectively (Martelli and Puccio, 2014). 
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Cellular iron uptake 
Cellular iron uptake from the circulation is accomplished through receptor-mediated 
endocytosis. Transferrin receptors on the cell surface bind the transferrin molecule that 
contains iron (Tf-Fe) and the complex is endocytosed. Tf receptors are of two types – 
transferrin receptors 1 and 1 (TfR1 and TfR2) (Kawabata et al., 1999). TfR1 is the receptor 
involved in cellular iron uptake. It is seen present in all cells, unlike TfR2, which is seen 
only in hepatocytes and erythroblasts.  
 
After endocytosis, the Tf-Fe complex in the endosome dissociates into Fe3+ and transferrin. 
This dissociation happens at an acidic pH, generated by Na-H-ATPase in the endosome. 
The ferric iron released is converted to ferrous iron by a ferrireductase, STEAP3 (six 
transmembrane epithelial antigen of prostate-3 (Ohgami et al., 2005). Ferrous iron is 
transported out of the endosome into cytosol by DMT-1 (Fleming et al., 1998). The 
transferrin receptors are recycled back to the plasma membrane (Klausner et al., 1983). 
This chain of events constitutes the transferrin cycle. 
  
Iron taken up by cells is used to meet cellular needs such as synthesis of hemoglobin, Fe-S 
clusters, etc. Once the cell’s needs for iron are met, excess cellular iron is stored in the 
form of ferritin. 
 
Ferritin 
Ferritin is a hetropolymer made up of 24 protein subunits made up of H (heavy) and L 
(light chains). It is expressed in all cells. It forms a shell-like structure around the bound 
iron. The H chain of ferritin has a catalytic property and converts ferrous form of iron to its 
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ferric form (Lawson et al., 1989). Iron inside the ferritin molecule can be easily mobilized 
whenever there is a demand for iron ( Burtis et al., 2012). Ferritin is also found in serum;  
this consists of L chains and it exists in glycated form (Santambrogio et al., 1987). Serum 
ferritin is used as an index of iron stores (Cook et al., 1974). Its levels are decreased in iron 
deficiency. However,  it is also an acute phase reactant and its levels are increased in acute 
or chronic inflammation (Lipschitz et al., 1974). This makes it an unreliable indicator of 
iron deficiency in the presence of inflammation.  
 
 
CELLULAR IRON HOMEOSTASIS 
 
Cellular iron homeostasis is achieved by regulating the levels of proteins involved in 
storage and transport of iron across cell plasma membranes. These include ferritin and 
transferrin. These proteins are subjected to post-transcriptional regulation (Hentze et al., 
1987). Such regulation occurs by alterations in mRNA stability and by repression of 
translation. Iron responsive elements (IRE) in the mRNA of these proteins play a vital role 
in such regulation. IREs are hairpin loop-like domains in the 5' or 3' UTR (untranslated 
region) of the genes concerned. The location of the IRE for each gene differs, with the 
ones for ferritin (Leibold and Munro, 1988), ferroportin, mitochondrial aconitase (Zheng et 
al., 1992), erythroid 5-aminolevulinic acid synthase(Cox et al., 1991) and hypoxia-
inducible factor alpha (HIF2-alpha (Sanchez et al., 2007) found in the 5' end, while the one 
for transferrin receptor 1 (TfR1) is found  in the 3' end. IREs provide binding sites for iron-
response proteins (IRPs)(Anderson et al., 2012), which are cytosolic proteins that are 
sensitive to variations in cellular iron.  
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IRPs are of two types- IRP1 and IRP2 (Murray et al., 2012). When a cell is iron-replete, 
iron forms Fe-S clusters and prevents the binding of IRPs to the IREs on the mRNAs of 
iron-related proteins described above. This facilitates translation of ferritin mRNA, but not 
that for TfR1. When a cell is iron-depleted, IRPs bind to IREs at the 5' and 3' ends of 
UTRs. If it binds to the 5' end, the translation of ferritin is repressed (translational arrest); 
if it binds at the 3' end, it promotes translation of TfR1. IRP1 has dual functions; it 
functions as cytosolic aconitase when iron levels are high and binds IRE when iron levels 
are low (Zheng et al., 1992). 
 
SYSTEMIC IRON HOMEOSTASIS 
 
As mentioned earlier, mammals have no physiological means of excreting iron. Intestinal 
iron absorption is tightly regulated to maintain homeostasis. Hepcidin is the master 
regulator of systemic iron homeostasis (Ganz, 2006).  
 
Role of hepcidin in systemic iron homeostasis 
Hepcidin, a 25-amino acid peptide, is the master regulator of systemic iron homeostasis. It 
has 8 cysteine residues, approximately 30% amino acid residues. It is synthesized mainly 
in the liver, as an 84-amino acid precursor, pro-hepcidin. This undergoes proteolysis to 
form hepcidin, which is the active form. Hepcidin was first isolated from blood 
ultrafiltrates, as a result of search of peptides with antimicrobial properties. It was called 
liver-expressed anti-microbial peptide (LEAP), as it was found to be highly expressed in 
the liver (Krause et al., 2000). Later, it was isolated in urine and was named hepcidin (Park 
et al., 2001).  
 
	   14	  
Numerous studies have highlighted the importance of hepcidin in iron homeostasis. The 
first link between hepcidin and iron metabolism was suggested by showing that iron 
overload in mice stimulated hepcidin production (Pigeon et al., 2001). Further, it was 
shown that iron overload occurred in hepatocytes and low iron levels were found in 
macrophages in mice in which upstream stimulatory factor-2 (USF-2) was knocked out. 
Those knock out mice were found to be hepcidin-deficient (Nicolas et al., 2001). It was 
also shown that mice that overexpressed hepcidin had severe iron deficiency anemia 
(Nicolas et al., 2001). Studies on juvenile hemochromatosis revealed mutations in the 
hepcidin gene (Roetto et al., 2004).  
 
Hepcidin regulates systemic iron homeostasis by acting on the iron exporter protein, 
ferroportin. As mentioned above, ferroportin is the only known iron export protein in 
mammalian cells and is found in enterocytes, macrophages and the placenta. Hepcidin 
binds to ferroportin causing it to be internalized; it then undergoes ubiquitin-mediated 
proteasomal degradation. Thus, high levels of hepcidin result in low ferroportin levels and 
vice versa. 
 
REGULATION OF HEPCIDIN SYNTHESIS 
 
Hepcidin synthesis is regulated by various factors such as iron status, inflammation, 
hypoxia, and erythroid activity. All these factors act at the transcriptional level. Some of 
them are positive regulators, while others are negative regulators. Low iron status, 
increased erythropoiesis and hypoxia are negative regulators of hepcidin (Nicolas et al., 
2002; Sasaki et al., 2012). Increased iron levels and inflammation up-regulate hepcidin 
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levels. Inflammation up-regulates hepcidin synthesis and hence, it is a positive acute phase 
reactant (Nemeth et al., 2003).  
 
Iron and hepcidin 
Availability of iron regulates hepcidin transcription; increased serum iron levels up-
regulate hepcidin transcription and vice versa. This is mediated through two main 
pathways.  
1. Hfe-transferrin receptor-2 (HFE-TfR2) pathway 
2. HJV-BMP (hemojuvelin-bone morphogenic protein) pathway 
 
Hfe-TfR2 pathway 
This pathway involves two main proteins - Hfe and TfR2. Hfe is a transmembrane protein, 
predominantly expressed in hepatocytes (Zhang et al., 2004). It is structurally similar to 
major histocompatibility complex (MHC) class I molecule and consists of α1, α2, α3 and α4 
domains and β2 microglobulin (Feder et al., 1997). The α1 and α2 domains of Hfe interact 
with the ectodomain of TfR1 to form a complex (Bennett et al., 2000). This affinity of this 
binding weakens when TfR1 binds holo-transferrin (Tf-Fe), because binding sites of Hfe 
and Tf-Fe overlap (Feder et al., 1998). This causes displacement of Hfe from TfR1, and 
promotes its binding with TfR2. 
 
TfR2 shares 45 % homology with TfR1 and is predominantly expressed in hepatocytes. 
Unlike TfR1, it has the capacity to bind both Tf-Fe and Hfe simultaneously (Chen et al., 
2007; Gao et al., 2009). Upon Hfe binding to TfR2, it causes upregulation of hepcidin 
transcription (Schmidt et al., 2008). TfR2 is not considered important in cellular iron 
uptake. Instead, it appears to act as a sensor for circulating iron levels (Johnson et al., 
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2007; Johnson and Enns, 2004; Robb and Wessling-Resnick, 2004). Thus, when 
circulating iron levels are high, the binding of Hfe to TfR2 increases, resulting in increased 
hepcidin transcription (Schmidt et al., 2008). 
 
HJV-BMP signaling pathway (hemojuvelin-bone morphogenic protein) 
Bone morphogenic proteins, known for their roles in growth, differentiation and cell 
signaling, belong to the transforming growth factor–β (TGF- β) superfamily. They are 
recognized by bone morphogenic protein receptors  (BMPR), which are serine-threonine 
kinases. Two types of BMPRs are known – BMPR I and II. These undergo hetero-
dimerization, along with co-receptor haemojuvelin, upon binding with its ligand BMP. 
This leads to receptor-activated SMAD (R-SMAD) protein phosphorylation, which 
complexes with co-SMAD proteins to form a transcription factor (Shi and Massagué, 
2003) (Figure 1).   
 
BMP-6 is involved in iron-mediated induction of hepcidin transcription (Andriopoulos et 
al., 2009). It is secreted from non-parenchymal cells of the liver, in response to increased 
cellular iron levels and it acts in a paracrine fashion (Enns et al., 2013). Its co-receptor is 
haemojuvelin (HJV), which helps in formation of a complex with BMP6 and BMP-6 
receptor (Babitt et al., 2005). This complex induces phosphorylation of R-SMAD proteins, 
especially SMAD-4. Phosphorylated SMAD-4 increases hepcidin transcription (Wang et 
al., 2005). SMAD-7 is a negative regulator of hepcidin. It inhibits SMAD-4 mediated 
upregulation (Mleczko-Sanecka et al., 2010) 
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Figure 1. Regulation of hepcidin by iron bioavailability 
 
 
 
 
 
(Hentze et al., 2010) 
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Inflammation and hepcidin 
Inflammation is mediated by pro-inflammatory cytokines such as interleukin-6 (IL-6) and 
tumor necrosis factor-alpha.  IL-6 is known to increase hepcidin levels (Nemeth et al., 
2003;  Nemeth et al., 2004a).  This results in sequestration of iron in macrophages 
involved in recycling of iron from senescent RBCs, leading to anemia of chronic disease.  
 
IL-6 acts via JAK/STAT (Janus kinase/signal transducer and activator of transcription) 
signaling to increase hepcidin transcription (Wrighting and Andrews, 2006). This pathway 
also cross-talks with the SMAD pathway, which mediates BMP/HJV signaling  (Wang et 
al., 2005).  
 
 In addition, inflammation also dysregulates erythropoiesis. IL-6 has been shown to 
decrease the responsiveness of erythroid precursors to erythropoietin (Adamson, 2009). 
This leads to impaired production of mature RBCs and results in anemia 
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Figure 2. Regulation of hepcidin by IL-6 during inflammation 
 
 
 
 
 
(Ganz et al., 2011) 
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Hepcidin and erythroid precursors 
 
Erythropoiesis is the process of production of mature red blood corpuscles from erythroid 
precursors. This process occurs as a normal physiological phenomenon. Apart from normal 
physiology, erythropoiesis can also occur in response to stress conditons such as hypoxia; 
this is referred to as stress erythropoiesis. In such cases, erythroid precursors have a high 
demand for iron. The main hormone involved in this process is erythropoietin (EPO), 
secreted by the kidney and liver (Pak et al., 2006). Increased levels of EPO down-regulate  
hepcidin transcription (Robach et al., 2009). A similar effect was seen in healthy 
volunteers in response to phlebotomy (Ashby et al., 2010).  
 
In other conditions of stress erythropoiesis such as thalassemia, other regulators of 
hepcidin, such as growth differentiation factor-15 (GDF-15) (Tanno et al., 2007a) and  
twisted gastrulation factor (TWGF) (Tanno et al., 2009), have also been reported; these 
down-regulate hepcidin transcription. More recently, erythroferrone (ERFE), another 
factor secreted by erythroblasts in response to EPO, has been shown to down-regulate 
hepcidin transcription through the JAK-STAT5 pathway (Kautz et al., 2014).  
 
These erythroid regulators are thought to maintain hepcidin levels in situations of stress 
erythropoiesis.  The role of erythroid regulators in steady state erythropoiesis is not clearly 
known. 
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Figure 3. Regulation of hepcidin by erythroid regulators 
 
 
 
 
(Hentze et al., 2010) 
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THE AXIS OF INFLAMMATION, HEPCIDIN, IRON AND ANEMIA 
 
Anemia of chronic disease (ACD) or anemia of inflammation (AI) is commonly seen in 
chronic inflammatory disorders, such as inflammatory bowel disease, rheumatoid arthritis 
and chronic kidney disease.  This condition is characterized by hypoferremia, low 
transferrin saturation and a normocytic normochromic anemia, and represents a condition 
of functional iron deficiency (Weiss and Goodnough, 2005).  
 
Increased levels of inflammatory cytokines are said to play a major role in the 
pathogenesis of ACD. As mentioned earlier, inflammation affects erythropoietin 
production, responsiveness of erythroblasts to EPO, red blood cell survival and availability 
of iron for erythroid precursors (Means, 1995). Pro-inflammatory cytokines, such as 
interleukin-1(IL-1) and tumor necrosis factor-α (TNF-α), suppressed EPO expression in 
hepatoma cell lines and isolated rat kidney cells (Jelkmann, 1998). Interferon-γ (IFN-γ), 
another pro-inflammatory cytokine, was found to down-regulate EPO receptors in 
erythroid precursor cells (Taniguchi et al., 1997; Wang et al., 1995).  
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HEPCIDIN AND ULCERATIVE COLITIS 
 
Ulcerative colitis (UC) is a chronic disease of the digestive tract. It is a disease of 
remissions and exacerbations. It warrants life-long treatment. Anemia is a significant co-
morbidity in this condition and it affects the quality of life in such patients (Pizzi et al., 
2006; Wells et al., 2006). Iron deficiency and anemia of inflammation are two major 
causes of anemia in patients with UC. Differentiation of these two types of anemias is 
essential to institute appropriate treatment. In case of ACD, treating the underlying cause 
will restore hemoglobin levels; however, but in a disease condition that has frequent 
remissions and exacerbations, the anemia is likely to recur. The major presenting symptom 
of ulcerative colitis patients is intermittent rectal bleeding, which predisposes the patient to 
develop iron deficiency anemia (IDA). In this situation, it is necessary to treat the anemia.  
 
Hepcidin levels have been reported to be increased in patients with ACD (Guagnozzi and 
Lucendo, 2014; Theurl et al., 2009). However, other studies have reported that hepcidin 
levels are lower in patients with ACD, who have IDA (Theurl et al., 2010). Similarly, 
Sukumaran et al (2014) have demonstrated lowered serum hepcidin levels in patients with 
ulcerative colitis, who had co-existent anemia.  Another study has reported lowered serum 
hepcidin, irrespective of the presence or absence of iron deficiency (Arnold et al., 2009).  
 
It is possible that serum hepcidin levels may help differentiate anemia of chronic disease 
from anemia due to iron deficiency. The potential utility of this differentiation may be in 
identifying patients in whom oral iron supplementation may be useful. 	  	  
	  
	  	  
	  
	  
	  
	  
	  
	  
THE STUDY  
	  	   24	  
	  
	  
BACKGROUND OF THE STUDY 
 
Anemia is a common complication of inflammatory bowel disease (IBD), which comprises 
Crohn’s disease (CD) and ulcerative colitis (UC). Hepcidin is known to be the central 
regulator of iron homeostasis in the body.  Previous work has shown that serum hepcidin 
levels were decreased in patients with ulcerative colitis, who had co-existent anemia. This 
observation is in contrast to other studies that have reported elevations in serum hepcidin 
levels in patients with inflammatory bowel disease. 
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AIM 
 
The aim of the present study was to test the hypothesis that when anemia and inflammation 
co-exist in patients with UC, the effect of anemia on hepcidin predominates over that of 
inflammation.  
 
OBJECTIVES 
 
The objectives of the present study were to  
1. estimate serum hepcidin levels in patients with ulcerative colitis 
2. determine whether serum hepcidin levels in these patients correlated with 
markers of anemia and/or inflammation  
 
The study was approved by the Institutional Review Board (IRB) at Christian Medical 
College (CMC), Vellore, India (IRB Min No. 8823 dated 07.04.2014).	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EQUIPMENT USED: 
 
1. Elix and Milli-Q ultrapure water systems (Millipore, USA) 
2. Table top centrifuge (Thermo Scientific Multifuge 3S+ Centrifuge) 
3. -70oC degree freezer (Thermo Scientific) 
4. Micro plate reader (Model 680, Bio-Rad Laboratories Inc., UK) 
 
CHEMICALS AND REAGENTS USED FOR ESTIMATION OF HEPCIDIN: 
 
Chemicals and reagents for estimation of hepcidin were obtained from Peninsula 
Laboratories (Bachem Group, San Carlos, USA). They consisted of the following: 
1. Standard diluent (peptide-free human serum) 
2. Lyophilized standard, anti-serum against hepcidin, biotinylated peptide 
3. Enzyme immunoassay buffer (EIA), streptavidin horseradish peroxidase (HRP), 
substrate solution (TMB - 3, 3', 5, 5' - tetramethylbenzidine solution) and stop solution 
(2N HCl) 
 
MISCELLANEOUS CONSUMABLES USED 
 
1. Vacutainer blood collection tubes (BD Biosciences, Plymouth, UK) 
2. Micro tips (Tarson Products Private Limited, Kolkata, India) 
3. Eppendorf tubes (Tarson Products Private Limited, Kolkata, India)  
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SUBJECTS 
 
A total of 59 patients were recruited into the study. Forty patients who met inclusion and 
exclusion criteria for the study and who were diagnosed to have ulcerative colitis (UC), by 
standard consensus criteria, served as cases.  
 
Inclusion criteria: 
1. Adults aged between 19-60 years diagnosed to have UC 
2. The diagnosis of UC was based on consensus criteria (clinical picture, endoscopic 
appearance and histopathology), where an infective etiology has been excluded. 
3. Patients were on/off treatment and had active/quiescent disease. 
 
Exclusion criteria: 
1. Patients with severe manifestations of UC 
2. Patients on erythropoietin and iron supplements 
3. Patients not willing to participate in the study  
 
Nineteen patients who attended the Gastroenterology OPD for investigation of dyspepsia 
and who were found to have no detectable abnormalities, were non-anemic  (Hb values 
equal to or more than 12 g/dL for females and equal to or more than 13 g/dL for males) 
and who had no evidence of inflammation (serum CRP values less than 6 mg/dL) served as 
control subjects.  
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Informed consent 
Patients, who were identified on the basis of inclusion and exclusion criteria as listed 
above, were invited to participate in the study. They were each provided with an 
information sheet in either English or a vernacular language of their preference. Written 
consent was obtained from patients who expressed their willingness to participate 
(enclosed in Appendix 3). Clinical and socio-demographic data for each patient were 
obtained in the proforma used (enclosed in Appendix 2).  
 
CALCULATION OF SAMPLE SIZE 
The sample size that was required to show a relationship between serum hepcidin levels 
and other parameters of interest was 62 subjects, with 80% power and 5% significance 
level with an expected correlation of 0.7. This figure was based on data from the 
publication by Basseri et.al (2013).  
The formula that was used for sample size calculation was as follows: 
 
n  =  (Z 1-α/2 + Z 1-β)2/ [FZ (ρ1) - FZ (ρ0)]2   + 3 
 
(Ref. for the above formula: Machin D, Campbell MJ, Fayers MP and Pinal APY. Sample 
size tables for clinical studies. Blackwell Science Ltd., 2nd Edition, 1997) 
where, 
n = sample size 
ρ1 = sample correlation coefficient, i.e. correlation between two variables in the sample 
(denoted by 'r' in current practice) 
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ρ0 = population correlation coefficient, i.e. correlation between two variables in the 
population (denoted by 'R' or  'ρ' in current practice) 
1-α/2 = desired confidence level   
1-β = power 
Z = standard deviation scores, taken from Z score table. 
FZ = cumulative distribution function  
 
Substituting the formula with power of 80 (β = 0.2), significance level of 5% (α = 0.05), 
and an expected correlation of 0.7  
 
n  =  (Z 1-0.025 + Z 1-.2)2/ [FZ (0.723) - FZ (0.5)]2   + 3 
 
Substituting for the Z deviates of the corresponding values in the formula, the calculated 
number of subjects was 62. However, the amount of funds sanctioned by CMC, Vellore for 
MD theses is a maximum of Rs. 100,000. The amount of reagents and chemicals that could 
be purchased for this amount sufficed only for estimation of serum hepcidin, ferritin, iron, 
total iron binding capacity (TIBC) and C-reactive protein from 40 patients. Hence, 40 
subjects with ulcerative colitis were studied. 
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SAMPLE COLLECTION 
 
After obtaining informed consent, samples were  collected from patients by venipuncture; 
blood was collected in BD vacutainer tubes. Approximately 6 ml of blood was collected 
from each patient.   
 
PROCESSING OF SAMPLES 
 
To obtain serum, the clotted blood was centrifuged at 2500 rpm, within 2 hours of blood 
collection. Serum was separated and divided into multiple aliquots. Parameters such as 
hemoglobin (Hb), mean corpuscular volume (MCV), total protein, albumin and erythrocyte 
sedimentation rate (ESR) were obtained from the hospital records of the patients, wherever 
available. 
 
STORAGE OF SAMPLES 
 
Aliquots of serum samples obtained were stored at -70oC. They were used for estimation of 
serum hepcidin, C- reactive protein (CRP) , serum iron and serum ferriitn. 
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ESTIMATION OF SERUM HEPCIDIN 
 
Reagents for estimation of serum hepcidin were purchased from Peninsula Laboratories 
(Bachem group, San Carlos, USA) 
 
Principle of the method 
The method used was based on a competitive immunoassay. Anti-rabbit antibody against 
hepcidin-25 was coated on a 96-well plate. A fixed concentration of biotinylated tracer 
(Bt-tracer) and varying concentrations of the standard or the peptide in the diluted serum 
samples competed for binding to the anti-serum. The captured Bt-tracer was subsequently 
bound by streptavidin-conjugated horseradish peroxidase (SA-HRP), which produced a 
colored product when substrate was added.     
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Figure 4. Competitive enzyme immunoassay for serum hepcidin 
 
 
 
 
(Enzyme immunoassay protocols, Kit insert) 
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Components in the kit 
1. 96-well plate  
2. Enzyme immunoassay buffer (EIA) (50 ml) 
3. Standard lyophilized hepcidin peptide (1 µg) 
4. Standard diluents (8 ml) (peptide-free human serum) 
5. Anti-serum against hepcidin-25 (lyophilized powder) 
6. Lyophilized powder of biotinylated peptide 
7. Streptavidin-horseradish peroxidase (SA-HRP  - 100 µl) 
8. Substrate solution (TMB- 3, 3', 5, 5'-tetramethylbenzidine) (11 ml of TMB and 
hydrogen peroxide[H2O2]) 
9. Stop solution (2N hydrochloric acid, 15 ml) 
 
As per the manufacturer’s instructions, standard diluent, lyophilized anti-serum, standard 
and biotinylated peptide were stored at -20°C. The EIA buffer, SA-HRP, substrate solution 
and stop solution were stored in a refrigerator at 2-4°C. These reagents were stable for one 
year under these conditions.  
 
Preparation of the reagents  
The unopened kit and reagents were equilibrated to room temperature before preparation 
of samples and working reagents. 
 
1. Stock standard: To 1 µg of lyophilized standard, 1 ml of diluent was added and 
mixed, using a vortex mixer. 
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2. Samples: The 40 samples in the study were diluted 1 in 10 (12 µl of sample + 108 µl 
of standard diluent) 
3. Enzyme immunoassay buffer (EIA buffer): EIA buffer (50 ml) was diluted to 1000 
ml with sterile deionized water (18 MOhm) and mixed well. 
4. Anti-serum: 5 ml of EIA buffer was added to the lyophilized anti-serum and mixed, 
using a vortex mixer. 
5. Biotinylated tracer (Bt-tracer): 5 ml of EIA buffer was added to the lyophilized 
powder of the Bt-tracer.  
6. Streptavidin-HRP: The tube was vortexed before dilution. It was diluted 1 in 200 
with EIA buffer (60 µl of SA-HRP with 12 ml of EIA buffer) and mixed, using a 
vortex mixer.  
 
 
Standard ng / ml Range: 0.02-25 ng/ml 
Stock 1000  
S1 25.00 Added 5 µl stock + 195 µl diluent  
S2 6.25 Added 40 µl S1 + 120 µl diluent 
S3 1.56 Added 40 µl S2 + 120 µl diluent 
S4 0.39 Added 40 µl S3 + 120 µl diluent 
S5 0.10 Added 40 µl S4 + 120 µl diluent 
S6 0.02 Added 40 µl S5 + 120 µl diluent 
S0 0.00 120 µl diluent 
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Lay out of 96-well plate microtitre plate used in the study 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A B B T1 T1 T9 T9 T17 T17 T25 T25 T33 T33 
B S1 S1 T2 T2 T10 T10 T18 T18 T26 T26 T34 T34 
C S2 S2 T3 T3 T11 T11 T19 T19 T27 T27 T35 T35 
D S3 S3 T4 T4 T12 T12 T20 T20 T28 T28 T36 T36 
E S4 S4 T5 T5 T13 T13 T21 T21 T29 T29 T37 T37 
F S5 S5 T6 T6 T14 T14 T22 T22 T30 T30 T38 T38 
G S6 S6 T7 T7 T15 T15 T23 T23 T31 T31 T39 T39 
H S0 S0 T8 T8 T16 T16 T24 T24 T32 T32 T40 T40 
 
B- Blank, S - Standards, T- Test samples 
 
Procedure 
Step 1: Added 25 µl of anti-serum to each well and 25 µl of EIA buffer to the blank well.      
Incubated at room temperature for 1 hour. 
Step 2: Added 50 µl of diluted standard/ sample to each well and 50 µl of diluent in the 
blank well. Incubated at room temperature for 2 hours. 
Step 3: Rehydrated the biotinylated tracer (Bt-tracer) with EIA buffer and added 25 µl of 
Bt-tracer per well. 
Step 4: Sealed the micro-titer plate cling film and incubated the plate at 4°C in a 
refrigerator overnight.  
Step 5: Re-equilibrated the microtiter plate to room temperature the next day.  
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Step 6:  Washed each well in the plate 5 times, with 300 µl of EIA buffer per well each 
time.  
Step 7: Added 100 µl per well of SA-HRP (substrate solution) to each well. Incubated at 
room temperature for 1 hour.  
Step 8: Washed each well in the plate 5 times, with 300 µl of EIA buffer per well each 
time.  
Step 9: Added 100 µl of TMB (substrate solution) per well. Incubated at room temperature 
for 30-60 minutes.  
Step 10: Readings were taken at 650 nm, during development of blue color. 
Step 11: Terminated the reaction with 100 µl of 2N HCl per well 
Step 12: Readings were taken at 450 nm, within 10 minutes of termination of reaction.  
 
Readings of optical density (OD) were obtained, using the software microplate manger of 
the ELISA plate reader.  
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Image of micro titer plate after termination of reaction 
 
 
 
 
A standard curve was plotted on a semi-log scale, using Microsoft Office, Excel 2011. The 
mean of the OD readings for each standard was used for the y-axis and the concentration 
of the standards (ng/ml) for the x-axis. Serum hepcidin levels in the samples were 
calculated, by four parameters logistic regression analysis, using the following formula. 
 
 
 
 
 
y	  =	  {a-­‐d/1+	  (x/c)	  b}	  +	  d	  
	  38	  	  
The equation was used to calculate the value of fit and plot "smooth line of fit". The four 
parameters a (maximum), b (slope), c (IC50, point of inflection) and d (minimum) were 
adjusted, till the value of fit was satisfied and the fit was good.  
 
 
 
The equation was used to calculate the concentration of the samples, expressed in ng/mL. 
   
 
ESTIMATION OF C-REACTIVE PROTEIN (CRP) 
 
CRP levels in the serum samples were estimated in the Department of Microbiology, 
CMC, Vellore. 
 
Equipment used:  
The reagents and equipment used for estimation of CRP were manufactured by Siemens 
GmbH, Germany. The nephelometer used was BN Prospec, Siemens GmbH, Marburg, 
Germany.  
 
Principle of the method (particle-enhanced nephelometry) 
Polystyrene particles, coated with monoclonal antibodies specific to human CRP, bound 
with CRP in the test sample and formed aggregates. A beam of light was passed through 
the solution containing these aggregates. Light was scattered by the aggregates.  The 
x	  =	  c	  (y-­‐a/d-­‐y)1/b	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intensity of the scattered light was directly proportional to the concentration of CRP in the 
sample. The result was calculated by comparison with a standard of known concentration. 
 
Reference interval:  < 6 mg/L 
 
ESTIMATION OF SERUM FERRITIN 
 
Estimation of serum ferritin was done in the Department of Clinical Biochemistry, CMC, 
Vellore. 
 
Analyzer used:  Siemens, ADVIA Centaur Immunoassay system Xpi, UK 
 
Principle of the method (two-site sandwich immunoassay using direct 
chemiluminescence technology) 
Two anti-ferritin antibodies were used in this method. The first antibody was polyclonal 
goat anti-ferritin antibody, labelled with acridinium ester.  The second antibody was 
monoclonal mouse anti-ferritin antibody, which was covalently coupled to paramagnetic 
particles. These antibodies were sequentially added to the reaction chamber. These 
antibodies bound the ferritin molecule present in the serum sample. On adding substrate 
(0.1 N nitric acid, 0.5% hydrogen peroxide and alkaline medium), acridinium ester was 
excited and released a photon, which was measured in terms of relative light units (RLU). 
The amount of ferritin present in the sample was directly proportional to the amount of 
RLUs detected by the system. 
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Reference interval: 
Men and women  > 50 years  -    20-320 ng/mL 
Women  < 50 years     -    10-290 ng/mL 
 
ESTIMATION OF SERUM IRON 
 
Estimation of serum iron was carried out in the Department of Clinical Biochemistry, 
CMC, Vellore.  
 
Analyzer used: Roche Cobas c 702 modular analyzer 
 
Principle of the method: guanidine/ ferrozine spectrophotometric method 
Transferrin-bound ferric ions in the sample were released by guanidine, and reduced to 
ferrous form by means of hydroxylamine. Ferrous ions reacted with ferrozine to form a 
purple colored complex. The absorbance of the sample was measured at 560 nm, using 
spectrophotometry. The intensity of the color obtained was directly proportional to the 
concentration of iron in the sample. 
 
Reference interval:  
Male        -   60- 160 µg/dL 
Female   -   40-145 µg/dL 
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ESTIMATION OF TOTAL IRON BINDING CAPACITY (TIBC) 
 
Estimation of serum iron was carried out in the Department of Clinical Biochemistry, 
CMC, Vellore.  
 
Analyzer used: Roche Cobas 8000c 702 modular analyzer 
 
Principle of the method:  
A known amount of ferrous iron was added to the sample at an alkaline pH. The ferrous 
ions bound to transferrin at unsaturated iron binding sites.  The unbound ferrous ions were 
measured using the ferrozine method (described above under the estimation of serum iron). 
The difference between the amount of ferrous ions added and the unbound ions measured 
was taken to be the unsaturated iron binding capacity (UIBC) of the sample.  
 
TIBC was calculated as the sum of serum iron concentration and the UIBC. 
 
UIBC = [Amount of ferrous ion added] - [Amount of unbound ferrous ion]  
 
TIBC = Serum iron + UIBC 
 
Reference interval:  
Male       -   300-400 µg/dL 
Female  -   250-350 µg/dL 
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CALCULATION OF TRANSFERRIN SATURATION (TSAT) 
 
It was calculated as the ratio of serum iron and total iron binding capacity, multiplied by 
100.  
 
TSAT  =  (Serum Iron / TIBC) * 100 
 
Reference interval: 
  
Adults - 25 - 50 % 
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STATISTICAL ANALYSIS 
 
 
Statistical analysis of data was done using the Statistical Package for Social Sciences  
(SPSS), version 16. The data were checked for normality of distribution, using 
Kolmogorov-Smirnov test.  Data were analyzed by parametric and non-parametric tests, as 
appropriate. Data of the two groups were compared using unpaired t-test, in case of 
normally distributed data, and Mann-Whitney U test for data that were not normally 
distributed. Correlation analysis was done using Pearson's correlation coefficient for 
normally distributed data and Spearman's correlation coefficient for data that were not 
normally distributed. A p- value of less than 0.05 was considered to be statistically 
significant in all cases.	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PART- I 
 
Distribution of data 
Data on age and hemoglobin were found to be normally distributed. Data for C-reactive 
protein, ferritin, iron, and hepcidin were found to have skewed distributions.  
	  
	  
Characteristics	  of	  subjects	  of	  the	  study 
A total of 59 patients were recruited into the study. Forty patients who met inclusion and 
exclusion criteria for the study and who were diagnosed to have ulcerative colitis (UC), by 
standard consensus criteria, served as cases. Nineteen patients who attended the 
Gastroenterology OPD for investigation of dyspepsia and who were found to have no 
detectable abnormalities, were non-anemic  (Hb values equal to or more than 12 g/dL for 
females and equal to or more than 13 g/dL for males) and who had no evidence of 
inflammation (serum CRP values less than 6 mg/dL) served as control subjects.  
 
The characteristics of subjects in the study are shown in Table 1.  
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Table 1 
 
Characteristic Control patients Patients with 
ulcerative colitis 
 
Number of patients  
 
19 
 
40 
 
Male/Female  
 
10/9 
 
22/18 
 
Age in years  
 
(mean + SD) 
 
39.47 
 
(12.77) 
 
41.7 
 
(9.12) 
 
 
 
Patients with ulcerative colitis comprised 22 males (55%) and 18 females (45%), while 
control subjects comprised 10 males (53%) and 9 females (47%). The ages of those with 
UC were similar to those of control subjects. 
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Figure 5. Hemoglobin levels in control subjects and patients with UC 
 
 
Data are shown as mean (+SD).  
*p <0.05 when compared with control data 
 
Hemoglobin levels were significantly lower in patients with ulcerative colitis than in 
control subjects. Among the 40 patients with ulcerative colitis, 21 (53%) were found to be 
anemic (Hb < 12 g/dL in females and <13 g/dL in males).  
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Figure 6.  Serum iron levels in control subjects and patients with UC 
 
 
Data are shown in the form of box and whisker plots, with quartiles and medians shown. 
An outlier is shown as a numbered dot.  
*p <0.05 when compared with control data 
 
Serum iron levels were significantly lower in patients with ulcerative colitis than in control 
subjects. 
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Figure 7.  Serum ferritin levels in control subjects and patients with UC 
 
 
 
 
Data are shown in the form of box and whisker plots, with quartiles and medians shown. 
Outliers are shown as numbered dots.  
 
Serum ferritin levels were similar in patients with ulcerative colitis and control subjects. 
 
 
 
 
 
 
 
	  49	  	  
Figure 8.  Serum CRP in control subjects and patients with UC 
 
 
 
 
Data are shown as box and whisker plots, with medians and interquartile ranges, as shown. 
Outliers are shown as numbered dots. 
*p <0.05 when compared with control data 
 
Serum CRP levels were significantly higher in patients with ulcerative colitis than in 
control subjects. 
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Serum hepcidin levels 
A standard curve for serum hepcidin levels was generated, using the microplate manager 
software from Bio-Rad laboratories. The concentration of each sample was obtained from 
this standard curve. 
 
Figure 9.  Standard curve for serum hepcidin 
 
 
 
The fit curve was generated as per the manufacturer’s instructions. The concentration of 
hepcidin in each sample was calculated from the optical density readings, after drawing a 
line for best fit. 
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Figure 10. Serum hepcidin levels in control subjects and patients with UC 
 
 
 
Data are shown as box and whisker plots, with medians and quartiles shown.  
*p <0.05 when compared with control data 
 
Serum hepcidin levels were found to be significantly lower in patients with UC than in 
control subjects.  
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Correlation analysis 
Correlation analysis was done on the data obtained. The data are represented as scatterplots 
with correlation coefficient (r) and p values shown.  
 
Figure 11. Scatterplot of serum hepcidin versus hemoglobin 
 
 
 
Serum hepcidin levels and hemoglobin values were found to have a significant positive 
correlation. 
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Figure 12. Scatterplot of serum hepcidin versus serum iron 
 
 
 
 
 
Serum hepcidin levels and serum iron values were found to have a significant positive 
correlation. 
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Figure 13. Scatterplot of serum hepcidin versus serum ferritin 
 
 
 
Serum hepcidin and serum ferritin values were found to have a significant positive 
correlation. 
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Figure 14. Scatterplot of hemoglobin versus serum iron 
 
 
 
 
 
Hemoglobin and serum iron values were found to have a significant positive correlation. 
 
 
 
 
 
 
 
 
 
Serum iron (µg/dL) 
	  56	  	  
Figure 15. Scatterplot of hemoglobin versus serum ferritin 
 
 
 
Hemoglobin and serum ferritin values were found to have a significant positive correlation. 
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Figure 16. Scatterplot of hemoglobin versus serum CRP 
 
 
 
 
 
Hemoglobin and serum CRP values were found to have a significant negative correlation. 
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Figure 17. Scatterplot of serum ferritin versus serum iron 
 
 
 
 
Serum ferritin and serum iron values were found to have a significant positive correlation. 
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Figure 18. Scatterplot of serum iron versus serum CRP 
 
 
 
Serum iron and CRP values were found to have a significant negative correlation. 
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Summary of results in Part-I 
 
1. Hemoglobin and serum iron and hepcidin levels were significantly lower in patients with 
ulcerative colitis, compared to control patients. 
 
2. Levels of serum CRP were significantly higher in patients with ulcerative colitis than in 
control patients. 
 
3. Correlational analyses showed the following: 
i. Levels of serum hepcidin correlated positively with hemoglobin, 
iron and ferritin. 
ii. Levels of hemoglobin correlated negatively with those of serum C-
reactive protein and positively with levels of serum iron and ferritin.  
iii. Serum ferritin and iron levels showed significant positive 
correlations with one another.  
iv. Serum iron levels correlated negatively with levels of C-reactive 
protein.   
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PART-II 
 
For additional analysis, subjects in the ulcerative colitis group were stratified based on 
anemic status. Patients were diagnosed to be anemic if their hemoglobin level was less 
than 13 g/dL for men and less than 12 g/dL for women. 
 
Table 2.  Patients with UC with and without anemia 
 
 
 
In patients with ulcerative colitis, 21 (53%) were found to be anemic and 19 (47%) were 
found non-anemic. Anemic group comprised of 9 males and 12 females, non-anemic group 
comprised of 13 males and 6 females. The age is similar in between anemic and non-
anemic group  
 
 
 Anemic Non-anemic 
 
Number of 
subjects with UC 
 
 
21 
 
19 
Male/Female 9/12 13/6 
 
Age in years 
(mean+SD) 
40.47 
(8.727) 
42 
(9.527) 
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Figure 19. Hemoglobin levels in anemic and non-anemic patients with 
ulcerative colitis 
 
 
 
Data are shown as mean + SD.  
*p <0.05 when compared with non-anemic group 
 
Haemoglobin levels in patients with UC, who were anemic, were significantly lower than 
in those without anemia. 
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Figure 20.  Serum ferritin levels in anemic and non-anemic patients with 
ulcerative colitis 
 
 
*p <0.05 when compared with non-anemic group 
 
Serum ferritin levels in patients with UC, who were anemic, were significantly lower than 
in those without anemia. 
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Figure 21.  Serum iron levels in anemic and non-anemic patients with 
ulcerative colitis 
 
 
 
 
Data are represented as box and whisker plot with medians and quartiles shown.  
*p <0.05 when compared with non-anemic group 
 
Serum iron levels in patients with UC, who were anemic, were significantly lower than in 
those without anemia. 
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Figure 22. Serum TIBC levels in anemic and non-anemic patients with 
ulcerative colitis 
 
 
 
Serum TIBC levels in patients with UC were similar in anemic and non-anemic group. 
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Figure 23. Transferrin saturation in anemic and non-anemic patients 
with ulcerative colitis 
 
 
 
Data are represented as box and whisker plots with medians and quartiles shown.  
*p <0.05 when compared with non-anemic group 
 
Transferrin saturation levels in patients with UC, who were anemic, were significantly 
lower than in those without anemia. 
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Figure 24. Serum CRP levels in anemic and non-anemic patients with 
ulcerative colitis 
 
 
 
Data are represented as box and whisker plots with medians and quartiles shown.  
*p <0.05 when compared with non-anemic group 
 
Serum CRP levels in patients with UC, who were anemic, were significantly higher than in 
those without anemia 
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Figure 25.  Serum hepcidin levels in anemic and non-anemic patients 
with ulcerative colitis 
 
 
 
Data are represented as box and whisker plots with medians and quartiles shown.  
*p <0.05 when compared with non-anemic group 
 
Serum hepcidin levels in patients with UC, who were anemic, were significantly lower 
than in those without anemia. 
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Summary of the findings in Part-II 
 
1. Hemoglobin and serum ferritin, iron and hepcidin levels and transferrin saturation 
values were significantly lower in patients with UC who were anemic, than in those 
who were not.  
 2. Serum CRP levels were significantly higher in patients with UC who were anemic, 
than in those who were not.	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DISCUSSION 
 
Anemia, is a significant co-morbidity in patients with ulcerative colitis (Cucino and 
Sonnenberg, 2001). Its prevalence is highly variable, with reported figures ranging from 
6% to 74% (Kulnigg and Gasche, 2006; Wilson et al., 2004). The etiology of the anemia is 
complex and varied. Causes include iron deficiency due to blood loss, inflammation per se, 
vitamin B12 and folate deficiency,  myelosuppression and autoimmune hemolytic anemia 
(Guagnozzi and Lucendo, 2014). Of these, iron deficiency and anemia of inflammation are 
the most common causes of anemia in ulcerative colitis (Kulnigg and Gasche, 2006). 
However, despite the reported high and alarming prevalence of anemia in ulcerative colitis 
resulting in significant co-morbidity, the anemia is often untreated or treated improperly in 
clinical practice (Nissenson et al., 2003). The reason for this is mainly in the difficulty 
involved in determining the etiology of anemia in this condition. This is vital in instituting 
appropriate treatment.  
 
Hepcidin, a 25-amino acid peptide, is the master regulator of systemic iron homeostasis 
(Ganz, 2006). Its levels are increased in inflammatory and iron-overloaded states and 
decreased in iron deficiency and hypoxia (Nicolas et al., 2002). In inflammatory 
conditions, such as ulcerative colitis, levels of pro-inflammatory cytokines are increased.  
Interleukin 6 (IL-6), in particular, is known to induce hepcidin transcription and increase 
serum hepcidin levels (Nemeth et al., 2004a). Increased hepcidin levels reduce intestinal 
absorption of iron and its recycling from macrophages(Nemeth et al., 2004b). 
 
In the present study, a total of 59 subjects were studied. Of these, 40 were diagnosed to 
have ulcerative colitis (UC) and 19 served as control subjects. Of those with UC, 53% 
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were found to be anemic. Hemoglobin levels were significantly lower in patients with 
ulcerative colitis than in control subjects. Serum iron and ferritin were considered as 
markers of iron status. Serum iron levels were significantly lower in ulcerative colitis 
patients suggesting hypoferremia. Serum ferritin levels were similar in between two 
groups.  
 
Shanmugam et al (2012) have shown that hepcidin expression was decreased in 2 different 
mouse models of colitis. However, there is no information in this study, however, on 
serum levels of hepcidin. Studies in humans have reported both increased (Basseri et al., 
2013; Oustamanolakis et al., 2011; Semrin et al., 2006; Theurl et al., 2009) and decreased 
levels of serum hepcidin in patients with inflammatory conditions (Arnold et al., 2009; 
Sukumaran et al., 2014; Theurl et al., 2009).  The differences would appear to be due to 
presence or absence of anemia. In the studies, which reported increased levels of hepcidin, 
the subjects were not anemic, while anemia was present in subjects in whom hepcidin 
levels were decreased.  Sukumaran et al (2014) have suggested that in chronic 
inflammatory conditions, hepcidin levels are likely to be increased in the early phase of the 
disease in response to inflammatory stimuli. High levels of hepcidin are implicated in the 
pathogenesis of anemia of inflammation(Basseri et al., 2013). With the development of 
anemia, hepcidin production is suppressed. This would account for the finding of 
decreased hepcidin levels in chronic inflammatory states with co-existent anemia.  This 
suggests that when both inflammation and anemia are seen in the same patient, the effect 
of anemia on hepcidin predominates over that of inflammation. This has also been 
suggested earlier by Theurl et al (2009).  
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Anemia in the patients in the present may have been due to either iron deficiency or 
anemia of chronic disease. With the data available, it is difficult to differentiate between 
the two. Measuring soluble transferrin receptor-log ferritin ratio (sTfR/log ferritin ratio) 
would be useful to differentiate between the two conditions. Soluble transferrin receptor 
expression is shown to be negatively affected by inflammation (Weiss, 2002) . However, 
the sTfR/log ferritin ratio is considered an accurate indicator of body iron stores in the 
presence of inflammation (Punnonen et al., 1997; Skikne et al., 2011). However, in this 
study, sTfR-log ferritin ratio could not be determined due to financial constraints involved 
in  estimating sTfR. 
 
Serum levels of CRP, a marker of inflammation, were elevated in patients with ulcerative 
colitis, indicating the presence of active inflammation. For further analysis, subjects in the 
ulcerative colitis group were stratified based on anemic status. Patients were diagnosed to 
be anemic if their hemoglobin level was less than 13 g/dL for men and less than 12 g/dL 
for women. Serum hepcidin levels were significantly lower in patients with UC who were 
anemic than in those who were not. Serum CRP levels were significantly higher in patients 
with UC who were anemic than in those who were not. Correlation analyses showed that 
levels of serum hepcidin correlated positively with hemoglobin, iron and ferritin but not 
with serum CRP. The observation that serum hepcidin correlated positively with 
hemoglobin is in contrast to other studies, which showed negative correlation between 
hepcidin and hemoglobin (Oustamanolakis et al., 2011). This may be accounted for by the 
postulate that as hemoglobin levels decrease due to iron-deficient erythropoiesis, hepcidin 
levels are downregulated. The converse would also hold true.  
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Based on the above findings, it appears that serum hepcidin levels were predominantly 
regulated by the iron status, rather than by the inflammation present in patients with 
ulcerative colitis. This supports the postulate by Sukumaran et al (2014) that when both 
anemia and inflammation coexist, the former predominates over the latter, resulting in 
lowered hepcidin levels.  Inflammation-induced increases in serum hepcidin levels are 
likely to lead to decreased serum iron levels, which in turn would cause iron-restricted 
erythropoiesis and anemia. This may lead to increased erythropoietic activity in response 
to anemia. Erythroid regulators produced in such situations, such as erythropoietin(Sasaki 
et al., 2012), GDF-15(Tanno et al., 2007b), TWSG1(Tanno et al., 2009) and 
erythroferrone(Kautz et al., 2014) are known to down-regulate hepcidin transcription . 
 
An earlier study conducted in the Department of Biochemistry, CMC, Vellore showed that 
serum GDF-15 levels were significantly increased patients with ulcerative colitis 
(unpublished observations). It is possible that increased GDF-15 levels may have cause 
decreased hepcidin levels. It was not possible to estimate levels of serum GDF-15 (or the 
other erythroid regulators) in the patients in the present study due to financial constraints 
and also because standardized assays for serum levels of these factors are not available.  
 
In this study, it was found that serum iron levels were significantly lower in patients with 
ulcerative colitis; serum iron levels negatively correlated with those of CRP. This finding 
of hypoferremia in the presence of inflammation suggests the presence of anemia of 
chronic disease. However, serum CRP levels did not correlate significantly with serum 
hepcidin levels.	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Conclusions 
 
Serum hepcidin levels were significantly lower in patients with UC than in control 
subjects; they were also lower in UC patients who were anemic than in UC patients who 
were not. Serum hepcidin correlated positively with markers of iron status (iron and 
ferritin) but not with a marker of inflammation (CRP). Hence, it appears that when anemia 
and inflammation coexist, the influence of anemia on hepcidin predominated over that of 
the inflammation.	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Limitations of the study 
 
1. The number of patients in the study was small (40 patients with UC and 19 
controls). 
 
2. Measurement of soluble transferrin receptor (sTfR) would have provided more 
information to help differentiate between anemia due to iron deficiency and anemia 
of chronic disease in the patients studied.  
 
 
3.  Measurement of serum levels of GDF-15, TWSG1, erythroferrone and IL-6 would 
have useful in elucidating the mechanisms that may be involved in hepcidin 
regulation in these patients. 
 
It was not possible to carry out assay for the parameters mentioned above due to financial 
constraints.   
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